Catherine Midyett
Family · Monroe, LANPI 1588965156
Payments from drug & device makers
Across 792 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AbbVie$2K
- Novartis$1K
- UCB, Inc.$864
- Bayer$793
- Pfizer$713
- plus $3K from 29 others
What the payments were for
- Food & beverage$12,40099%
- Education$1401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 218 | $3,353 |
| AbbVie | 147 | $2,289 |
| Novartis | 79 | $1,054 |
| UCB, Inc. | 52 | $864 |
| Bayer | 49 | $793 |
| Pfizer | 45 | $713 |
| Johnson & Johnson | 35 | $526 |
| GSK | 26 | $514 |
| Lilly USA, LLC | 24 | $365 |
| AstraZeneca(2 entities) | 19 | $334 |
| Genentech USA, Inc. | 14 | $254 |
| Cumberland Pharmaceuticals, Inc. | 8 | $168 |
| Sanofi | 9 | $160 |
| Novo Nordisk | 10 | $151 |
| Boehringer Ingelheim | 7 | $113 |
| Dexcom, Inc. | 6 | $107 |
| ANI Pharmaceuticals, Inc. | 6 | $104 |
| Abbott | 6 | $97 |
| Xeris Pharmaceuticals, Inc. | 5 | $96 |
| Mallinckrodt Hospital Products Inc. | 4 | $93 |
| Sandoz | 4 | $66 |
| United Therapeutics Corporation | 2 | $54 |
| Medtronic | 3 | $38 |
| Corcept Therapeutics | 2 | $35 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Sequel Med Tech, LLC | 1 | $23 |
| Sanofi-aventis U.S. LLC | 2 | $22 |
| Cequr Corporation | 1 | $21 |
| Fresenius Kabi USA, LLC | 1 | $18 |
| Insulet Corporation | 1 | $17 |
| Pacira Therapeutics, Inc. | 1 | $16 |
| Aurinia Pharma U.S., Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Organon | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BENLYSTA$125
How this compares
$12,540 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 223 | $249,536 |
| JardianceEmpagliflozin | 219 | $182,746 |
| OzempicSemaglutide | 139 | $161,475 |
| Tresiba Flextouch U-200Insulin Degludec | 113 | $106,517 |
| TrulicityDulaglutide | 74 | $85,403 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 77 | $59,670 |
| FarxigaDapagliflozin Propanediol | 72 | $50,328 |
| KerendiaFinerenone | 35 | $31,732 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $27,485 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $27,320 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 36 | $23,983 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $23,191 |
| Humulin R U-500Insulin Regular, Human | 17 | $22,506 |
| Novolog FlexpenInsulin Aspart | 135 | $20,729 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 20 | $19,160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $365 | $334,938297 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $113 | $201,906239 claims |
| Novo NordiskOzempic, Novolog | $151 | $169,356169 claims |
| AstraZenecaFarxiga | $334 | $50,32872 claims |
| BayerKerendia | $793 | $31,73235 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $22 | $9,39611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in Monroe
- Rebecca HoodMonroe$15K
- Gabrielle NicolleMonroe$14K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.